Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cepharanthine Dihydrochloride
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher’s Sairiyo Receives Approval to Start Phase 1 Trial of PD-001 (Cepharanthine)
Details : PD-001 (cepharanthine) is an approved, oral, small molecule natural product candidate. It is being evaluated for the treatment of cancer and covid-19 infection.
Brand Name : PD-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2024
Lead Product(s) : Cepharanthine Dihydrochloride
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher's Sairiyo Advances Development of Cepharanthine for Phase 1 Study in Australia
Details : PD-001 (cepharanthine) is an approved, oral, small molecule natural product candidate. It is being evaluated for the treatment of cancer and covid-19 infection.
Brand Name : PD-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 21, 2024
Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : PharmaTher
Deal Size : $0.2 million
Deal Type : Financing
Details : Sairiyo will use the net proceeds to advance developments of cepharanthine, for cancer and infectious diseases, and DMT PharmaPatch (N,N-dimethyltryptamine) as a potential treatment for ocular disease and neuropsychiatric conditions.
Brand Name : PharmaPatch
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : PharmaTher
Deal Size : $0.2 million
Deal Type : Financing
Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Pharmadrug Production GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
PharmaDrug Enters Definitive Agreement to Acquire Sairiyo Therapeutics
Details : Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 25, 2021
Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Pharmadrug Production GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?